Stay updated on REOLYSIN in KRAS Mutant CRC Clinical Trial
Sign up to get notified when there's something new on the REOLYSIN in KRAS Mutant CRC Clinical Trial page.
Latest updates to the REOLYSIN in KRAS Mutant CRC Clinical Trial page
- Check6 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedNo additions or deletions were observed. The page content appears unchanged.SummaryDifference0.1%
- Check34 days agoChange DetectedRevision: v3.4.2 added; the funding-lapse notice and Revision: v3.4.1 were removed; these are site-wide updates and do not affect the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
- Check41 days agoChange DetectedA site-wide notice about a lapse in government funding and the page revision updated to v3.4.1 were added, replacing the previous revision v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%
- Check48 days agoChange DetectedAdded a glossary toggle and updated QC-related wording (Last Update Submitted that Met QC Criteria) and the revision label (Revision: v3.4.0); No FEAR Act data wording was adjusted. These are metadata/UX changes and do not modify core study content, eligibility criteria, or results.SummaryDifference0.2%
- Check55 days agoChange DetectedCore components such as Bevacizumab, FOLFIRI, REOLYSIN, and related eligibility/intervention terms were removed from the record, altering how the study is described and who may be eligible to participate.SummaryDifference18%
Stay in the know with updates to REOLYSIN in KRAS Mutant CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the REOLYSIN in KRAS Mutant CRC Clinical Trial page.